Review paper on the risk of breast cancer in relation to gender, breast development and gonadal function published in JCEM

The Journal of Clinical Endocrinology & Metabolism has accepted the manuscript “Breast Cancer and Major Deviations of Genetic and Gender-related Structures and Function” for publication. The review reports of the risk of breast cancer (BC) in relation to gender, breast development and gonadal function in eight populations with different genetic conditions. Main three conclusions are: 1) the presence of an Y chromosome protects against the development of BC; 2) Without menstrual cycles, BC hardly occurs with an incidence comparable to males; 3) BC has been reported only once in genetic females with the Mayer-Rokitansky-Küster-Hauser syndrome, who have normal breasts and ovulating ovaries with normal levels of estrogens and progesterone.

For more information, please read the abstract.

 

Review paper on the use of high-dose estrogens (HDE) for the treatment of breast cancer

Review paper on the use of high-dose estrogens (HDE) for the treatment of breast cancer

Estrogens are known to stimulate the growth of breast cancer, whereas on the other hand estrogens are an effective treatment for this disease. The fact that estrogens can effectively be used for the treatment of breast cancer is something that almost has been forgotten about, whereas the fear for estrogens remains. This paper reviews the use of estrogens for the treatment of breast cancer and identifies possible applications for the future.

Coelingh Bennink et al Maturitas 2017 (HDE paper)

Results Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men published in The Journal of Clinical Endocrinology & Metabolism

Luteinizing hormone–releasing hormone agonists have replaced estrogens for endocrine treatment of advanced prostate cancer (PC) because of cardiovascular side effects. The published study with the fetal estrogen estetrol (E4) in healthy males shows promise as a safe and effective drug for use in prostate cancer.

A Dose-Escalating Study With the Fetal Estrogen JCEM 2018

IMPRINT

Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheibio.com

DISCLAIMER

The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

SOCIAL MEDIA